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Contribution 
What are the novel findings of this work? 
Based on the results of this meta-analysis both early-onset and late-onset PE represent risk factors 
for cardiovascular mortality and morbidity, however early-onset PE is associated with a higher risk 
of long-term adverse cardiovascular events compared to late-onset PE. 
What are the clinical implications of this work? 
Close surveillance of women with a history of PE is recommended, particularly of those who 
developed an early onset form which may act as an isolated major risk factor of cardiovascular 
events. In cases with previous late-onset PE lifestyle or medical interventions targeting the 
modifiable risk factors for adverse cardiovascular health are warranted.  
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ABSTRACT 
Objective 
To elucidate whether preeclampsia (PE) and the gestational age at onset of the disease (early-onset 
vs late-onset PE) has an impact on the risk of long-term cardiovascular complications. 
Methods 
MedLine and Scopus databases were searched until April 15, 2020 utilizing combinations of the 
relevant MeSH terms, key words, and word variants for “pre-eclampsia” “cardiovascular disease” 
and “outcome”. Inclusion criteria were: (a) cohort or case-control design; (b) inclusion of women 
with a diagnosis of pre-eclampsia at the time of the first pregnancy; (c) enough data to compare 
each outcome in: (I) women with a diagnosis of pre-eclampsia versus women with normal 
pregnancies and/or (II) women with early-onset pre-eclampsia versus women with late-onset pre-
eclampsia. The primary outcome was a composite score of cardiovascular morbidity including either 
maternal death, major cardiovascular and cerebrovascular events, hypertension need for anti-
hypertensive therapy, type 2 diabetes mellitus dyslipidaemia, metabolic syndrome; secondary 
outcomes were the individual components of the primary outcome analysed separately. Data were 
combined using a random-effect generic inverse variance approach. 
Results 
MOOSE guidelines and PRISMA statement were followed. Seventy-three studies were included. 
Women with a prior history of PE had a higher risk of cardiovascular morbidity during life (OR: 2.05, 
95% CI 1.9-2.3), death (OR: 2.18, 95% CI 1.73-1.93), major cardiovascular events (OR: 1.80, 95% CI 
1.6-2.0), hypertension (OR: 3.93, 95% CI 3.1-50), need for anti-hypertensive medication (OR: 4.44, 
95% CI 2.4-8.2), dyslipidaemia (OR: 1.32, 95% CI 1.3-1.4), diabetes (OR: 2.14, 95% CI 1.5-3.0), 
abnormal renal function (OR: 3.37, 95% CI 2.3-5.0) and metabolic syndrome (OR: 4.30, 95% CI 2.6-
7.1) compared to those with no history of PE. More importantly, the strength of this association 
persisted when considering women who had PE ≤1, 1 to 10 and >10 years before the occurrence of 
these outcomes. When stratifying the analysis according to time at onset of PE, women with 
previous early-onset PE were at higher risk of composite adverse cardiovascular outcome (OR: 1.75, 
95% CI 1.0-2.9), cardiovascular events (OR: 5.63, 95% CI 1.5-21.4) hypertension (OR: 1.48, 95% CI 
1.3-1.7), dyslipidaemia (OR: 1.51, 95% CI 1.3-1.8), abnormal renal function (OR: 1.51. 95% CI 1.1-
2.2) and metabolic syndrome (OR: 1.66, 95% CI 1.1-2.5) compared to women with late PE. 
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Conclusions 
Preeclampsia as well as early-onset and late-onset PE all represent risk factors for adverse 
cardiovascular events later in life. Early-onset PE is associated with a higher burden of cardiovascular 
mortality and morbidity compared to late-onset PE. 
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INTRODUCTION 
Preeclampsia (PE) is a leading cause of maternal and neonatal mortality and morbidity, complicating 
up to 5% of all pregnancies1-3, and is defined as new onset hypertension after 20 weeks of gestation 
plus involvement of at least one organ system4,5. 
Despite decades of research the aetiology of PE still remains unknown4. The abnormal 
throphoblastic invasion of myometrial spiral arteries has been historically considered the primum 
movens for PE, however more recent studies have supported the concept that PE may result as a 
consequence of suboptimal cardiovascular adaptation to the pregnancy either due to a pre-existing 
predisposition or to additional risk factors for cardiovascular disease (CVD)6,7. 
Available knowledge has led to the distinction of two subtypes of PE which are conventionally 
distinguished based on the gestational age at onset: early-onset PE, commonly associated with fetal 
growth restriction (FGR) and abnormal placentation, and late-onset PE, characterized by 
appropriate fetal growth and associated with metabolic or inflammatory maternal factors6,8,9. These 
differences have led to the hypothesis that early-onset and late-onset PE actually represent two 
different clinical entities sharing the common clinical manifestations of hypertension and 
proteinuria6,9. 
Over the past decades, cohort studies as well as systematic review and meta-analyses have shown 
a significantly higher risk of cardiac, cerebrovascular and peripheral arterial disease and 
cardiovascular mortality in women with history of PE compared with women with uncomplicated 
pregnancies10-19. Of note, cohort studies have shown that such risk is higher among women who 
developed preeclampsia before 37 weeks of gestation12,20,21. If we assume that early-onset and late-
onset PE represent different ends of the disease spectrum, it is reasonable to hypothesize a different 
long-term impact on the cardiovascular system, however, to our knowledge there is no systematic 
review specifically addressing the risk cardiovascular sequelae and risk factors for CVD according to 
the gestational age at diagnosis of the PE. The aim of this systematic review and meta-analysis is to 
explore the risk of cardiovascular mortality and morbidity in women with a history of PE based on 
evidence from recent literature and to elucidate whether the gestational age at onset of the disease 
(early-onset vs late-onset PE) is associated with a different risk of complications during life.  
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SOURCES 
Bibliographic search, study selection criteria and quality assessment 
MedLine, Embase and Scopus databases were initially searched to identify studies evaluating the 
incidence of: (1) composite adverse cardiovascular events (including cardio- and cerebrovascular 
diseases, cardiac death, hypertension, dyslipidemia, diabetes, metabolic syndrome, need for 
antihypertensive therapy); (2) cardiovascular and cerebrovascular diseases; (3) cardiac death; (4) 
diabetes; (5) hypertension; (6) dyslipidemia; (7) kidney disease (including either acute or chronic 
kidney disease and end-stage renal disease); (8) metabolic syndrome; (9) current antihypertensive 
therapy, in women with a prior PE diagnosis as compared to women with normal pregnancies. The 
bibliographic search was performed by three investigators (MEF, FDA and AD) up to April 15, 2020, 
and was adjusted for each database while maintaining a common overall architecture. We used 
various combinations of the following terms related to ten main domains: "pre-eclampsia OR 
preeclampsia OR EPH OR pregnancy toxemia OR edema-proteinuria-hypertension gestosis" 
(title/abstract) AND "cardiovascular disease*"(title/abstract) or "ischaemic heart disease OR 
ischemic heart disease OR coronary artery disease OR coronary heart disease OR myocardial 
infarction OR acute coronary syndrome"(title/abstract) or "stroke OR cerebrovascular disease OR 
cerebrovascular accident" (title/abstract) or "hypertension" (title/abstract) or "diabetes" 
(title/abstract) or "kidney disease OR renal impairment" (title/abstract) or "cholesterol* OR 
dyslipidemia" (title/abstract) or "metabolic syndrome*"  (title/abstract) or "antihypertensive*" 
(title/abstract). The reference lists of reviews and retrieved articles were also searched for 
additional pertinent papers, and no language restrictions were used. Only full text articles were 
considered eligible for the inclusion. Case reports, conference abstracts and case series with fewer 
than 3 cases were excluded to avoid publication bias. 
The study was registered with the PROSPERO database (Registration number: CRD42018107717). 
Inclusion criteria were: (a) cohort or case-control design; (b) inclusion of women with a diagnosis of 
pre-eclampsia at the time of the first pregnancy (if possible), or ever formulated, and documented 
through clinical chart, or hospital discharge abstract databases, or nationwide/local registries of 
pathologies, or specific questionnaires; (c) enough data to compare each outcome in: (I) women 
with a PE diagnosis versus women with normal pregnancies and/or (II) women with early-onset PE 
versus women with late-onset PE. PE was defined as new onset hypertension (≥140 mmHg systolic 
or ≥90 mmHg diastolic) at or after 20 weeks’ gestation in combination with the appearance of 
proteinuria (>0.3 grams/24 hours) after 20 weeks of gestation22. Early- and late-onset PE were 
defined as PE requiring delivery before or after 34 weeks of gestation, respectively. 
This article is protected by copyright. All rights reserved.
The assessment of long-term outcomes at different time-points after an index date are typically 
performed through longitudinal studies, with large samples and follow-up even lasting decades. 
Thus, re-analyses of the same cohort including updated follow-up information, and multiple 
publications on the same subjects are common. To avoid duplication of data, we selected and 
extracted the relevant information using the following criteria in order of priority: (1) availability of 
data; (2) longer follow-up; (3) larger sample size; (4) higher level of statistical adjustment (i.e. the 
multivariate model including the highest number of potential confounders).  
The primary outcome was to explore the risk of a composite score of cardiovascular morbidity 
including either any of the following events: 
• Maternal death 
• Major cardiovascular and cerebrovascular events including infarction, heart failure (any type), 
cerebral embolic, thrombotic, or hemorrhagic events lasting at least 30 min with or without 
persistent residual motor, sensory, or cognitive dysfunction and stroke 
• Hypertension, as defined by blood pressure (BP) >140/90 mmHg on two consecutive 
measurements23 
• Need for anti-hypertensive therapy 
• Type 2 diabetes mellitus, as defined either by HbA1c ≥ 6.5 % (≥ 48 mmol/mol) or by random plasma 
glucose ≥ 200 mg/dl (≥ 11.1 mmol/l) or by fasting plasma glucose ≥ 126 mg/dl (≥ 7.0 mmol/dl) or by 
OGTT 2-hour glucose in venous plasma ≥ 200 mg/dl (≥ 11.1 mmol/l)24 
• Dyslipidaemia, defined as the occurrence of any alteration in plasma cholesterol, mainly related to 
high-density and low-density lipoprotein cholesterol and plasma triglycerides25 
• Metabolic syndrome, as defined according to the criteria for the clinical diagnosis of metabolic 
syndrome proposed by the American Heart Association and including three out of five among 
elevated waist circumference, elevated triglycerides, reduced HDL-C, elevated blood pressure and 
elevated fasting glucose26 
Secondary outcomes were the individual components of the primary outcome analysed separately. 
Two authors (MEF, FDA) reviewed all abstracts independently. Agreement regarding potential 
relevance was reached by consensus. Full text copies of those papers were obtained, and the same 
reviewers independently extracted relevant data regarding study characteristics and pregnancy 
outcome. Inconsistencies were discussed by the reviewers and consensus reached or by discussion 
with a third author (AD). If more than one study was published on the same cohort with identical 
endpoints, the report containing the most comprehensive information on the population was 
included to avoid overlapping populations. For those articles in which information was not reported 
This article is protected by copyright. All rights reserved.
but the methodology was such that this information would have been recorded initially, the authors 
were contacted. 
Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) 
for observational studies. According to NOS, each study is judged on three broad perspectives: the 
selection of the study groups, the comparability of the groups, and the ascertainment outcome of 
interest. Assessment of the selection of a study includes the evaluation of the representativeness 
of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure and the 
demonstration that outcome of interest was not present at start of study. Assessment of the 
comparability of the study includes the evaluation of the comparability of cohorts based on the 
design or analysis. Finally, the ascertainment of the outcome of interest includes the evaluation of 
the type of the assessment of the outcome of interest, length and adequacy of follow-up. According 
to NOS, a study can be awarded a maximum of one star for each numbered item within the Selection 
and Outcome categories. A maximum of two stars can be given for Comparability27. 
Data analysis 
Data were combined using a random-effect generic inverse variance approach, which enables the 
inclusion of diverse estimates of Relative Risk (i.e. OR and HR) into the same meta-analysis. From 
each paper, we extracted the adjusted estimates of risk of each outcome, or, when these were not 
available, the unadjusted estimates. If a paper reported the results of different multivariate models, 
the most stringently controlled estimates (those from the model adjusting for more factors) were 
extracted. If different models controlled for the same number of covariates, the model containing 
the most relevant covariates was used for the analysis. When studies only reported separate 
estimates for early- and late-onset PE, the summary risk of each outcome was computed from the 
separate estimates available using a fixed-effect meta-analysis of the individual study data. 
The units of the meta-analysis were single comparisons of the rate of each outcome in women with 
a history of PE versus women with normal pregnancies. Stratified analyses were also performed to 
explore the association between pre-eclampsia and three of the nine outcomes (composite adverse 
cardiovascular events, cardio-cerebrovascular diseases and death) among: (1) women with early-
onset PE only and (2) women with late-onset PE only, both compared to women with normal 
pregnancies. Additional stratified analyses assessed the risk of the three outcomes separately by 
time between index pregnancy and outcomes occurrence (≤1 year; 1-10 years; >10 years). 
Moreover, to further explore the association between the exposure (PE) and cardiovascular 
morbidity, we compared each of the nine outcomes among women with a history of early-onset PE 
versus women with a history of late-onset PE.  
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When possible, sensitivity analyses were performed and all meta-analyses were re-run after the 
exclusion of studies with unadjusted estimates. Between-study heterogeneity was quantified using 
the I2 statistic, and, for the analyses including ≥10 publications, potential publication bias was 
assessed through funnel plots (displaying ORs from individual studies versus their precision 
(1/standard error). The meta-analysis was designed following the MOOSE guidelines28 and reported 
according to the Preferred Reporting Item for Systematic Reviews and Meta-analyses (PRISMA) 
statement29. All analyses were performed using RevMan software, version 5.3 (Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2014).  
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RESULTS 
General characteristics 
Overall, 73 studies were included in the systematic review12,20,21,30-99 (Table 1, Figure 1, 
Supplementary Table 1). 
The results of the quality assessment of the included studies using NOS are presented in 
Supplementary Table 2. Most of the included studies showed an overall good score regarding the 
selection and comparability of the study groups, and for ascertainment of the outcome of interest. 
The main weaknesses of these studies were their retrospective design, relatively small sample size 
and heterogeneity in the definition of the severity of PE. 
Preeclampsia vs no preeclampsia 
Fifty studies (including 10,966,043 women) explored the risk of composite cardiovascular morbidity 
in women who compared to those who did not experience PE during pregnancy (Table 2). Overall, 
women with a prior history of PE had a higher risk of cardiovascular morbidity during life, with an 
OR of 2.05, 95% CI (1.85-2.27) (Figure 2). When considering studies including adjusted models of 
cardiovascular disease, the risk of composite cardiovascular morbidity remained higher in women 
with PE compared to controls, with an OR of 1.99, 95% CI (1.79-2.22) (Figure 3). Furthermore, such 
relationship held true also when considering early-onset and late-onset PE vs controls (OR 3.79, 
95%CI (2.70-5.31) and 1.89 (1.53-2.33), respectively) (Figure 4). Finally, the association between a 
history of PE and composite cardiovascular morbidity remained significant even when considering 
different time intervals between pregnancy and the occurrence of the outcome (≤1, 1 to 10 and >10 
years) (Figure 5). 
Looking at the risk of cardiovascular and cerebrovascular diseases following preeclampsia, which 
was evaluated in 31 studies (Table 2), preeclampsia in pregnancy was associated with an almost 
two-fold higher risk compared to uncomplicated controls (OR 1.80, 95%CI (1.62-2.00) and OR 1.79, 
95%CI (1.61-2.01) for all studies and those including adjusted estimates only, respectively) (Figures 
6 and 7, respectively). Such relationship was confirmed for early-onset PE (OR 1.75, 95%CI (1.20-
2.55)) (Figure 8) and also when considering different time intervals between pregnancy and the 
occurrence of the outcome (≤1, 1 to 10 and >10 years) (Figure 9). 
Women with a prior history of PE had a higher risk of death (12 studies, OR 2.18, 95%CI (1.73-1.93)) 
(Table 2, Figure 10) compared to those whose pregnancy was not complicated by preeclampsia. 
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More importantly, the strength of this association persisted when considering the time of onset of 
the preeclampsia (OR 5.12, 95%CI (3.22-8.12) and 1.65, 95%CI (1.46-1.86) for early-onset and late-
onset PE, respectively) (Figure 11) as well as the timelag between preeclampsia and the occurrence 
of the outcome (Figure 12). 
Ten (1,728,478 women) and twenty-one studies (2,711,443 women) explored the risk of developing 
diabetes and hypertension following PE (Table 2). Overall, PE carried an increased risk of both 
conditions during life with an OR of 2.14 (1.52-3.02) for diabetes (Figure 13) and 3.93 (95% CI 3.08-
5.02) for hypertension (Figure 14); of note, women with history of PE had also a higher risk of 
requiring anti-hypertensive medication (OR 4.44, 95% CI 2.40-8.23) (Figure 15). 
When exploring the risk of medical complications, women with history of PE showed a significantly 
higher risk of developing dyslipidaemia (OR: 1.32, 95% CI 1.27-1.37, kidney disease (OR: 3.37, 95% 
CI 2.28-5.00) as well as metabolic syndrome (OR: 4.30, 95% CI 2.61-7.08) compared to those with 
no history of PE (Figures 16-18). 
All the results were substantially confirmed when the analyses were repeated excluding old studies 
which did not provide adjusted estimated (Table 2). 
Early-onset vs late-onset preeclampsia 
Four studies (including 2,979 women) explored the risk of composite cardiovascular morbidity in 
women who compared to those who did not experience PE during pregnancy (Table 3, Figures 19-
24). Women with previous early-onset PE were at increased risk of composite adverse 
cardiovascular outcome (OR: 1.75, 95% CI 1.03-2.99), cardiovascular and cerebrovascular diseases 
(OR: 5.63, 95% CI 1.48-21.4), hypertension (OR: 1.48, 95% CI 1.26-1.72), dyslipidaemia (OR: 1.51, 
95% CI 1.25-1.83), kidney disease (OR: 1.51. 95% CI 1.06-2.18) and metabolic syndrome (OR: 1.66, 
95% CI 1.08-2.54) compared to women with late PE. 
Again, all the results were confirmed following the exclusion of the studies without adjusted 
estimates.  
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DISCUSSION 
Main findings 
This systematic review with meta-analysis has confirmed that the risk of cardiovascular mortality 
and morbidity in women with history of PE is significantly higher compared with those women with 
past normotensive pregnancy. Based on our findings, the long-term risk of composite adverse 
cardiovascular outcome, major cardiovascular events and other complications including CV death, 
hypertension and metabolic syndrome was at least two-fold higher in women with previous PE 
compared to those with no history of PE. In women who had early- and late-onset PE the risk of 
composite adverse cardiovascular outcome and death was almost four- and two-fold higher, 
respectively, compared to women with no history of PE, however a higher burden on the 
cardiovascular health was demonstrated for early-onset PE compared to late-onset PE. 
Clinical significance of this study in respect of previous studies 
A series of studies have consistently shown a higher risk of cardiac, cerebrovascular and peripheral 
arterial disease and cardiovascular mortality in women with history of PE compared to women with 
uncomplicated pregnancies12,58,84,100. A systematic review and meta-analysis including over 3 million 
cases and almost 200000 pregnancies complicated by PE demonstrated significantly increased risks 
of hypertension, major CV events and mortality following PE10, and similar results were found in two 
other meta-analyses11,13.  A recent cohort study which included over 1 million of women confirmed 
a higher risk of chronic hypertension in women who had a pregnancy complicated by preeclampsia 
compared to those with no history of PE42. Other cohort studies12,20,21 showed an increased risk of 
ischemic heart disease, stroke and death from cardiovascular causes among women who had 
preeclampsia and a preterm delivery. Women experiencing preeclampsia and small-for-gestational 
age (SGA) offspring had increased risk of developing subsequent hypertension. The risk of 
developing congestive heart failure, ischemic heart disease and stroke was also increased when 
adding SGA and preterm delivery to a pregnancy complicated by preeclampsia20,21. The severity of 
preeclampsia also increased the risk of later ischaemic heart disease but not to the same extent as 
the gestation of onset. To our knowledge this present systematic review and meta-analysis first 
reports that preeclampsia leading to delivery before 34 weeks of gestation is associated with a 
higher burden of cardiovascular morbidity and mortality compared to preeclampsia associated with 
delivery beyond 34 weeks. Such finding supports previous hypothesis suggesting different subtypes 
of PE whose pathophysiology and long-term impact on cardiovascular health seems different9. The 
potential influence of genetic or epigenetic factors on the occurrence of either subtype of PE is 
currently under investigation101,102. 
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Interpretation 
The findings from our work confirm that early-onset PE represents a strong independent risk factor 
for the development of CVD later in life, being associated with a significantly higher risk of all the 
evaluated adverse outcomes. A higher risk for adverse cardiovascular events was also demonstrated 
for women with history of late onset PE although the magnitude of this increase seems greater for 
those with early onset form. 
If we assume that the pathophysiology of the cardiovascular risk following PE is based on a 
permanent myocardial and vascular impairment – which in most cases may persist as subclinical 
following delivery – the results of our meta-analysis suggest that the extent of this impairment is 
more severe in those women developing early-onset disease. 
A higher risk of composite adverse outcome and death was also found in women with history of 
late-onset PE compared to controls, albeit of a less extent compared to early-onset PE. We 
hypothesize this to be related to the fact that most of the women with late-onset PE present some 
modifiable risk factors which may be mitigated later in life such as obesity, dyslipidemia or insulin 
resistance103-115. 
On this ground, we recommend close surveillance of women with a history of preeclampsia and 
particularly of early-onset disease, while lifestyle or medical interventions on the acknowledged and 
modifiable risk factors remains warranted for the prevention of long-term cardiovascular 
complications. 
 
Recent data on preconception cardiovascular function has shown that before pregnancy, women 
who are subsequently affected by PE and/or FGR have a subclinical impairment of the  
hemodynamic function compared with those with subsequent normal pregnancy outcome7. 
Therefore, it is still unclear whether PE initiates the damage to the mother’s cardiovascular system 
which then leads to a higher risk of later-life CVD or whether PE and cardiovascular disorders share 
common risk factors preceding the pregnancy. Moreover, as recently suggested by the use of a 
competing risk approach, the presence of such risk factors among pregnant women seems to impact 
on the individual background risk and anticipate or delay the onset of preeclampsia104,105.  
Strengths and limitations 
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Thorough literature search and multitude of outcomes explored and stratification of the analysis 
according to early-onset and late-onset PE represent the major strengths of this work. 
Differences among the included populations in management of PE, heterogeneity in the definition 
of early-onset and late-onset PE, time at follow-up and outcome measures as well as heterogeneity 
in post-natal medical assessment are the main limitations of the present systematic review. 
Additionally, a good amount of the included studies did not report subgroup analysis according to 
the onset time of the disease, and some of the explored outcomes were affected by the very small 
number of included studies and even smaller number of events, thus limiting the robustness of the 
results. 
Another limitation is that the definitions of early-onset vs late-onset PE were most commonly based 
on the gestational age at delivery. Recent evidence has challenged this concept and suggested that 
the classification of the subtypes of PE should be based or on its association with fetal growth 
restriction or normally grown fetus)116,118. 
Additionally, we were unable to discriminate cases with recurrent PE, which may represent an 
indicator of a higher risk for future development of hypertension and CVD119.  
Conclusion 
In summary, both early- and late-onset PE are associated with increased risk of adverse 
cardiovascular outcome compared to controls with no prior PE, however women with history of 
early-onset PE are at higher risk of cardiovascular mortality and morbidity compared to those with 
history of late-onset disease.   
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Figure legends 
Figure 1. PRISMA flow diagram 
Figure 2. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - All studies. 
Figure 3. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - Adjusted estimates 
only. 
Figure 4. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of early-onset preeclampsia versus women with prior normal pregnancy status (a), and 
among women with a prior diagnosis of late-onset preeclampsia versus women with prior normal 
pregnancy status (b). 
Figure 5. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - By timelag between 
index pregnancy and outcome. 
Figure 6. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - All studies. 
Figure 7. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - Adjusted estimates 
only. 
Figure 8. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of early-onset preeclampsia versus women with prior normal pregnancy status. 
Figure 9. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - By timelag between 
index pregnancy and outcome. 
Figure 10. Pooled risk of death among women with a prior diagnosis of preeclampsia versus women 
with prior normal pregnancy status - All studies. 
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Figure 11. Pooled risk of death among women with a prior diagnosis of early-onset preeclampsia 
versus women with prior normal pregnancy status (a), and among women with a prior diagnosis of 
late-onset preeclampsia versus women with prior normal pregnancy status (b). 
Figure 12. Pooled risk of death among women with a prior diagnosis of preeclampsia versus women 
with prior normal pregnancy status - By timelag between index pregnancy and outcome. 
Figure 13. a) Pooled risk of diabetes among women with a prior diagnosis of preeclampsia versus 
women with prior normal pregnancy status - All studies. b) Pooled risk of diabetes among women 
with a prior diagnosis of preeclampsia versus women with prior normal pregnancy status - Adjusted 
estimates only. 
Figure 14. a) Pooled risk of hypertension among women with a prior diagnosis of preeclampsia 
versus women with prior normal pregnancy status - All studies. b) Pooled risk of hypertension 
among women with a prior diagnosis of preeclampsia versus women with prior normal pregnancy 
status - Adjusted estimates only. 
Figure 15. a) Pooled risk of anti-hypertensive therapy among women with a prior diagnosis of 
preeclampsia versus women with prior normal pregnancy status - All studies. b) Pooled risk of 
antihypertensive therapy among women with a prior diagnosis of preeclampsia versus women with 
prior normal pregnancy status - Adjusted estimates only. 
Figure 16. a) Pooled risk of dyslipidemia among women with a prior diagnosis of preeclampsia 
versus women with prior normal pregnancy status - All studies. b) Pooled risk of dyslipidemia among 
women with a prior diagnosis of preeclampsia versus women with prior normal pregnancy status - 
Adjusted estimates only. 
Figure 17. a) Pooled risk of kidney disease among women with a prior diagnosis of preeclampsia 
versus women with prior normal pregnancy status - All studies. b) Pooled risk of kidney disease 
among women with a prior diagnosis of preeclampsia versus women with prior normal pregnancy 
status - Adjusted estimates only. 
Figure 18. a) Pooled risk of metabolic syndrome among women with a prior diagnosis of 
preeclampsia versus women with prior normal pregnancy status - All studies. b) Pooled risk of 
metabolic syndrome among women with a prior diagnosis of preeclampsia versus women with prior 
normal pregnancy status - Adjusted estimates only. 
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Figure 19. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of early-onset preeclampsia versus women with a prior diagnosis of late-onset 
preeclampsia - All studies. 
Figure 20. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of early-onset preeclampsia versus women with a prior diagnosis of late-onset 
preeclampsia - All studies. 
Figure 21. Pooled risk of hypertension among women with a prior diagnosis of early-onset 
preeclampsia versus women with a prior diagnosis of late-onset preeclampsia - All studies. 
Figure 22. Pooled risk of dyslipidemia among women with a prior diagnosis of early-onset 
preeclampsia versus women with a prior diagnosis of late-onset preeclampsia - All studies. 
Figure 23. Pooled risk of kidney disease among women with a prior diagnosis of early-onset 
preeclampsia versus women with a prior diagnosis of late-onset preeclampsia - All studies. 
Figure 24. Pooled risk of metabolic syndrome among women with a prior diagnosis of early-onset 
preeclampsia versus women with a prior diagnosis of late-onset preeclampsia - All studies. 
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Table 1. Characteristics of the included studies. 




Extracted outcomes Sub-analyses by time of PE onset 
1 Callaway30 2007 Am J Obstet Gynecol Australia Cohort 3639 21 years Diabetes NR 
2 Callaway31 2011 Austr NZ J Obstet Gynecol Australia Cohort 2112 21 years Composite AE; Hypertension NR 
3 Thornton32 2013 Am J Obstet Gynecol Australia Cohort 691,738 1 year Composite AE; CV mortality NR 
4 Tooher33 2017 Hypertension Australia Cohort 31,656 20 years Composite AE; CV events; Hypertension; Abnormal renal function NR 
5 Forest34 2005 Obstet Gynecol Canada Cohort 336 8 years Composite AE; Metabolic syndrome NR 
6 Ray35 2005 Lancet Canada Cohort 1,026,265 9 years Composite AE; CV events NR 
7 Smith36 2012 J Obstet Gynecol Can Canada Cohort 120 3 years Metabolic syndrome NR 
8 Mehrabadi37 2014 BMJ Canada Cohort 2,193,425 Acute (no other details) Abnormal renal function NR 
9 Grandi38 2017 Circulation Canada Cohort 156,967 NR Composite AE; CV events; Hypertension NR 
10 Dai39 2018 J Obstet Gynecol Can Canada Cohort 1,598,043 12 years (median) Abnormal renal function NR 
11 Langlois40 2020 Can J Cardiol Canada Cohort 165,558 16 years (median) Composite AE; CV events Early PE vs controls 
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12 Lykke21 2009 Hypertension Denmark Cohort 782,287 14.6 years (mean) Composite AE; CV events; Diabetes NR 
13 Lykke41 2010 Pediatr Perinat Epidemiol Denmark Cohort 782,287 14.6 years (mean) Death NR 
14 Behrens42 2017 BMJ Denmark Cohort 1,025,118 10 to 14 years  Hypertension NR 
15 Kristensen43 2019 BMJ Denmark Cohort 1,772,330 18.6 years (mean) Abnormal renal function Early PE vs controls; late PE vs controls 
16 Haukkamaa44 2004 Am J Cardiol Finland Case-control 352 >20 years Composite AE; CV events NR 
17 Mannisto45 2013 Circulation Finland Cohort 10,314 39.4years (mean) Composite AE; CV events; Death; Diabetes; Hypertension NR 
18 Hubel46 2000 BJOG Iceland Case-control 60 30 years Composite AE; Anti-hypertensive medication Early PE vs controls 
19 Funai47 2005 Epidemiology Israel Cohort 37,061 24-36 years Composite AE; Death NR 
20 Kessous48 2015 Heart Israel Cohort 96,280 11 years (mean) Composite AE; CV events; Abnormal renal function NR 
21 Blaauw49 2006 Obstet Gynecol Netherland Cohort 44 3 to 13 months Abnormal renal function NR 
22 Gaugler-Senden50 2008 
Eur J Obstet Gynecol Repr 
Biol Netherland Case-control 40 5.5 years Composite AE; Hypertension NR 
23 Nijdam51 2009 BMC Fam Pract Netherland Cohort 185 3 years Composite AE; CV events; Hypertension; Dyslipidemia NR 
24 Stekkinger52 2009 Obstet Gynecol Netherland Cohort 849 ≥6 months 
Composite AE; Hypertension; 
Dyslipidemia; Metabolic syndrome; 
Abnormal renal function  
Early vs late PE 
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25 Aukes53 2012 BJOG Netherland Cohort 148 5 years Composite AE; CV events Early vs late PE 
26 Hermes54 2013 Am J Obstet Gynecol Netherland Cohort 405 2.5 years Composite AE; Hypertension; Metabolic syndrome NR 
27 Scholten55 2013 Obstet Gynecol Netherland Cohort 1234 6 to 12 months  Hypertension; Dyslipidemia; Metabolic syndrome  Early vs late PE 
28 Veerbek56 2015 Hypertension Netherland Cohort 748 3 months to 5 years 
Composite AE; Hypertension; Metabolic 
syndrome; Anti-hypertensive medications  Early vs late PE 
29 van Rijn57 2016 Hypertension Netherland Cohort 73 1.5 to 3.5 years Composite AE; Diabetes; Hypertension; Abnormal renal function Early PE vs controls 
30 Bokslag58 2017 Am J Obstet Gynecol Netherland Cohort 187 9 to 16 years 
Composite AE; Hypertension; Use of 
anti-hyper medication; Metabolic 
syndrome 
Early PE vs controls 
31 Irgens Ψ 12 2001 BMJ Norway Cohort 626,272 13 years 
Composite AE (Death Included only in 
sub-analyses: same cohort of Vikse 2008 
and Skjaerven 2012) 
Early PE vs controls; late 
PE vs controls 
32 Vikse59 2008 NEJM Norway Cohort 570,433 26.5 years (mean) Abnormal renal function (end-stage renal disease) NR 
33 Kvehaugen60 2011 Hypertension Norway Cohort 43 5 to 8 years Composite AE; Medication NR 
34 Andersgaard61 2012 Am J Obstet Gynecol Norway Cohort 9974 ≥20 years Composite AE; CV events; Hypertension; Diabetes NR 
35 Skjaerven62 2012 BMJ Norway Cohort 836,147 25 years (median) Composite AE; Death Early PE vs controls; late PE vs controls 
36 Riise20 2017 J Am Heart Assoc Norway Cohort 506,350 ≥7 years CV events NR 
37 Egeland63 2018 Circulation Norway Cohort 60,027 ≤10 years Hypertension; Anti-hypertensive medications NR 
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38 Wikstrom64 2005 Br J Obstet Gynecol Sweden Cohort 403,550 15 years Composite AE; CV events NR 
39 Nelander65 2016 BMJ Open Sweden Cohort 3232 12 years Composite AE; CV events NR 
40 Khashan66 2019 Plos Med Sweden Cohort 1,366,441 16.4 years (median) Abnormal renal function 
Early PE vs controls; late 
PE vs controls 
41 Tang67 2009 Stroke Taiwan Cohort 1,132,019 3 months to 1 year CV events NR 
42 Lin68 2011 Am J Cardiol Taiwan Cohort 1,132,064 3 years Composite AE; Death; CV events NR 
43 Wu69 2014 Am J Obstet Gynecol Taiwan Cohort 944,474 9 years (median) Abnormal renal function  NR 
44 Yeh70 2014 J Am Heart Assoc Taiwan Cohort 6300 6 years Composite AE; CV events; Hypertension NR 
45 Kuo71 2018 Taiwan J Obstet Gynecol Taiwan Cohort 6475 9.8 years (mean) Diabetes NR 
46 Hannaford72 1997 Heart UK Cohort 8244 ≈30 years Composite AE; CV events NR 
47 Melchiorre73 2011 Hypertension UK Case-control 112 2 years Composite AE; Hypertension NR 
48 Bhattacharya74 2012 Pregnancy Hypert UK Cohort 34,854 ≤50 years Composite AE; CV events; Death; Hypertension; Abnormal renal function NR 
49 Leon75 2019 Circulation UK Cohort 1,303,365 9.3 years (median) Composite AE; CV events; Death; Hypertension Early PE vs controls 
50 Thorogood76 1992 Am J Epidemiol UK (Engl, Wales) Case-control 841 NR Composite AE; CV events NR 
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51 Mann77 1976 Br J Prev Obst Med UK (England) Case-control 270 NR Composite AE; CV events NR 
52 Fraser78 2012 Circulation UK (England) Cohort 4376 16 to 20 years Composite AE; CV events NR 
53 Smith79 2001 Lancet UK (Scotland) Cohort 129,920 15 to 19 years Composite AE; Death; CV events NR 
54 Wilson80 2003 BMJ UK (Scotland) Cohort 3593 20 years Anti-hypertensive medications  NR 
55 Libby81 2007 Diabetologia UK (Scotland) Cohort 7187 >30 years Diabetes NR 
56 Ayansina82 2016 Pregn Hypert UK (Scotland) Cohort 77,941 ≈30 years 
Composite AE; Death; Abnormal renal 
function NR 
57 Rosenberg83 1983 JAMA USA Case-control 1057 NR Composite AE; CV events NR 
58 Kestenbaum84 2003 Am J Kidney Dis USA Cohort 124,141 7.8 years Composite AE; CV events NR 
59 Brown85 2006 Stroke USA Case-control 682 ≥42 days CV events NR 
60 Edlow86 2009 Am J Obstet Gynecol USA Case-control 219 6-13 months Hypertension; Diabetes; Dysplipidemia Early PE vs controls 
61 Srinivas87 2009 J Mat Fet Neonatal Med USA Case-control 368 NR Composite AE; Metabolic syndrome NR 
62 Mongraw-Chaffin88 2010 Hypertension USA Cohort 14,403 37 years (median) Composite AE; Death Early PE vs controls 
63 Hovsepian89 2014 Stroke USA Cohort 2,066,230 6 weeks Composite AE; CV events NR 
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64 Savitz90 2014 Am J Epidemiol USA Cohort 849,639 1 year Composite AE; CV events; Diabetes NR 
65 Cirillo91 2015 Circulation USA Cohort 14,062 ≈50 years Composite AE; Death Early PE vs controls; late PE vs controls 
66 Black92 2016 J Hypert USA Cohort 5960 ≤1 year Composite AE; Hypertension NR 
67 Cain93 2016 Am J Obstet Gynecol USA Cohort 302,689 5 years Composite AE; CV events NR 
68 White94 2016 Am J Obstet Gynecol USA Cohort 80 30 years Composite AE; CV events NR 
69 Best95 2017 Hypert Pregn USA Case-control 420 13 years (mean) Composite AE; Hypertension NR 
70 Kattah96 2017 Am J Kidney Dis USA Case-control 132 18 years (median) Abnormal renal function NR 
71 Stuart97 2018 Ann Intern Med USA Cohort 58,671 25 to 32 years Composite AE; Hypertension; Diabetes; Dylipidemia 
Early PE vs controls; late 
PE vs controls 
72 Ackerman98 2019 Am J Obstet Gynecol USA Cohort 569,900 Immediately post-partum Composite AE; CV events NR 
73 Haas99 2019 J Am Heart Assoc USA Cohort 4484 3.2 years (mean) Composite AE; Hypertension NR 
 
PE: Pre-eclampsia;  Composite AE: composite adverse cardiovascular events (including cardio- and cerebrovascular disease, cardiac death, hypertension, 
metabolic syndrome, need for anti-hypertensive therapy);   CV events: cardio- and cerebrovascular events;   Abnormal renal function: including either acute or 
chronic kidney disease and end-stage renal disease;  NR: Not reported. 
ΨAs the cohort of Irgens 2001 was partially overlapping with Vikse 2008 and Skjaevern 2012, the study was included only in the sub-analyses by time of PE 
onset. 
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Table 2. Pooled risk of each outcome among women with a prior diagnosis of pre-eclampsia versus women with prior normal pregnancy status (see Figures 2-24 for the 
references to the included studies).  
 
Outcomes 
N. of studies 






      
Composite adverse cardiovascular events A 50 (10,966,043) 8795 / 473,770 vs 77,529 / 8,816,146 1.85 vs 0.87  2.05 (1.85-2.27) 91 
Adjusted estimates only 41 (10,955,248) 7051 / 274,730 vs 59,955 / 6,157,885 2.57 vs 0.97 1.99 (1.79-2.22) 93 
      
Stratified by time of pre-eclampsia onset:      
- Early onset 11 (3,019,017) 4770 / 148,124 vs 41,300 / 2,868,663 3.22 vs 1.44 3.79 (2.70-5.31) 87 
- Late onset 5 (1,549,555) 2533 / 67,100 vs 22,322 / 1,480,225 3.77 vs 1.51 1.89 (1.53-2.33) 79 
      
Stratified by time between index pregnancy and outcome:      
- ≤1 year 6 (2,117,919) 360 / 203,008 vs 3024 / 1,914,911 0.18 vs 0.15 2.37 (1.87-3.01) 72 
- 1 to 10 years 15 (2,900,650) 1655 / 72,859 vs 22,530 / 2,636,683 2.27 vs 0.85 2.27 (1.86-2.76) 71 
- >10 years 24 (2,721,741) 6210 / 167,288 vs 46,301 / 2,314,978 3.71 vs 2.00 1.90 (1.64-2.19) 95 
      
      
Cardiovascular and cerebrovascular diseases 31 (10,763,599) 6440 / 510,316 vs 59,158 / 10,053,273 1.26 vs 0.59 1.80 (1.62-2.00) 86 
Adjusted estimates only 28 (10,753,319) 6097 / 509,307 vs 57,813 / 10,244,012 1.19 vs 0.56 1.79 (1.61-2.01) 93 
      
Stratified by time of pre-eclampsia onset:      
- Early onset 2 (1,468,923) 2113 / 80,740 vs 18,956 / 1,388,183 2.62 vs 1.36 1.75 (1.20-2.55) 86 
- Late onset 0 --  -- -- 
      
Stratified by time between index pregnancy and outcome:      
- ≤1 year 5 (3,768,831) 283 / 189,167 vs 2285 / 3,556,157 0.15 vs 0.08 2.61 (1.73-3.93) 85 
- 1 to 10 years 10 (4,401,547) 1704 / 101,995 vs 23,807 / 3,108,454 1.67 vs 0.77 2.01 (1.70-2.37) 70 
- >10 years 14 (1,680,677) 3624 / 121,832 vs 26,037 / 1,380,306 2.97 vs 1.89 1.55 (1.35-1.79) 92 
      
      
Death B 12 (5,064,156) 2861 / 119,570 vs 40,480 / 3,607,506 2.39 vs 1.12 2.18 (1.79-2.66) 71 
Stratified by time of pre-eclampsia onset:      
- Early onset 5 (2,794,249) 1472 / 83,082 vs 24,851 / 2,711,167 1.77 vs 0.92 5.12 (3.22-8.12) 58 
- Late onset 4 (1,490,884) 611 / 57,528 vs 7088 / 1,433,356 1.06 vs 0.49 1.65 (1.46-1.86) 0 
      
Stratified by time between index pregnancy and outcome:      
- ≤1 year 1 (691,738) 17 / 22,298 vs 80 / 669,440 0.08 vs 0.01 5.10 (3.07-8.47) -- 
- 1 to 10 years 2 (2,435,429) 861 / 25,554 vs 17,763 / 1,277,811 3.37 vs 1.39 2.21 (1.71-2.84) 0 
- >10 years 9 (1,936,989)   1.98 (1.62-2.43) 64 
      
Diabetes 10 (1,728,478) 1946 / 47,022 vs 9640 / 824,062 4.14 vs 1.17 2.14 (1.52-3.02) 95 
Adjusted estimates only 8 (1,718,431) 1636 / 46,077 vs 9640 / 816,846 3.55 vs 1.18 2.28 (1.58-3.28) 96 
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Hypertension 21 (2,711,443) 7296 / 78,982 vs 86,531 / 2,571,050 9.24 vs 3.37 3.93 (3.08-5.02) 99 
Adjusted estimates only 15 (2,695,024) 6873 / 77,787 vs 85,193 / 2,563,530 8.84 vs 3.32 3.74 (2.87-4.87) 99 
      
Dyslipidemia 3 (59,075) 6396 / 9686 vs 26,882 / 49,389 66.0 vs 54.4 1.32 (1.27-1.37) 0 
Adjusted estimates only 2 (58,890) 6396 / 9651 vs 26,881 / 49,239 66.3 vs 54.6 2.54 (0.81-2.95) 36 
      
Kidney disease C 14 (8,696,440) 779 / 203,916 vs 9278 / 6,186,679 0.38 vs 0.15 3.37 (2.28-5.00) 94 
Adjusted estimates only 12 (8,696,323) 775 / 203,850 vs 9278 / 6,186,628 0.38 vs 0.15 3.35 (2.25-5.00) 95 
      
Metabolic syndrome 5 (1416) 184 / 674 vs 38 / 742 27.3 vs 5.1 4.30 (2.61-7.08) 0 
Adjusted estimates only 4 (1229) 112 / 543 vs 29 / 686 20.6 vs 4.2 4.05 (2.42-6.77) 8 
      
Anti-hypertensive therapy 5 (63,910) 501 / 2898 vs 1207 / 61,012 17.3 vs 1.97 4.44 (2.40-8.23) 66 
Adjusted estimates only 2 (63,620) 417 / 2711 vs 1195 / 60,909 15.4 vs 1.96 4.22 (1.98-2.97) 89 
      
 
OR = Odds ratio; CI = Confidence Interval.   
* Number of women with the outcome / Total number of pre-eclamptic women vs Number of women with the outcome / Total number of healthy women. Some studies did not 
report raw data separately by exposure group, thus the sum of the total number of women in either group may be lower than the overall sample.   
A Including: cardio- and cerebrovascular disease, cardiac death, hypertension, metabolic syndrome, need for anti-hypertensive therapy.   B All adjusted estimates.   C Including 
either acute or chronic kidney disease and end-stage renal disease. 
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Table 3. Pooled risk of selected outcomes among women with a prior diagnosis of early pre-
eclampsia versus women with a prior diagnosis of late pre-eclampsia (see Figures 19-24 for the 
references to the included studies). 
 
Outcomes 





    
Composite adverse cardiovascular events A 4 (2979) 1.75 (1.03-2.99) 81 
    
Cardiovascular and cerebrovascular 
diseases 1 (148) 5.63 (1.48-21.4) -- 
    
Hypertension 2 (2083) 1.48 (1.26-1.72) 0 
    
Dyslipidemia 3 (2831) 1.51 (1.25-1.83) 0 
    
Kidney disease B 1 (849) 1.52 (1.06-2.18) -- 
    
Metabolic syndrome 3 (2831) 1.66 (1.08-2.54) 67 
    
 
OR = Odds ratio; CI = Confidence Interval. 
A Including: cardio- and cerebrovascular disease, cardiac death, hypertension, metabolic syndrome, 
need for anti-hypertensive therapy.   B Including either acute or chronic kidney disease and end-stage 
renal disease. 
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Figure 2. Pooled risk of composite adverse cardiovascular events among women with a prior 
























































Heterogeneity: Tau² = 0.08; Chi² = 556.98, df = 49 (P < 0.00001); I² = 91%
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Figure 3. Pooled risk of composite adverse cardiovascular events among women with a prior 






















































Heterogeneity: Tau² = 0.08; Chi² = 534.09, df = 40 (P < 0.00001); I² = 93%
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Figure 4. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of early-onset preeclampsia versus women with prior normal pregnancy status (a), and 
among women with a prior diagnosis of late-onset preeclampsia versus women with prior normal 





































Heterogeneity: Tau² = 0.19; Chi² = 77.84, df = 10 (P < 0.00001); I² = 87%
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Heterogeneity: Tau² = 0.03; Chi² = 18.85, df = 4 (P = 0.0008); I² = 79%
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Figure 5. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - By timelag between 














Heterogeneity: Tau² = 0.06; Chi² = 18.11, df = 5 (P = 0.003); I² = 72%


















Heterogeneity: Tau² = 0.06; Chi² = 47.64, df = 14 (P < 0.0001); I² = 71%



























Heterogeneity: Tau² = 0.09; Chi² = 459.54, df = 23 (P < 0.00001); I² = 95%
Test for overall effect: Z = 8.76 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 551.87, df = 44 (P < 0.00001); I² = 92%
Test for overall effect: Z = 13.28 (P < 0.00001)
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Figure 6. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 




Figure 7. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 




































Heterogeneity: Tau² = 0.05; Chi² = 215.30, df = 30 (P < 0.00001); I² = 86%
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Figure 8. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 




Figure 9. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of preeclampsia versus women with prior normal pregnancy status - By timelag between 
































Heterogeneity: Tau² = 0.05; Chi² = 212.63, df = 27 (P < 0.00001); I² = 87%
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Heterogeneity: Tau² = 0.06; Chi² = 7.10, df = 1 (P = 0.008); I² = 86%
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Figure 10. Pooled risk of death among women with a prior diagnosis of preeclampsia versus 










Heterogeneity: Tau² = 0.17; Chi² = 26.01, df = 4 (P < 0.0001); I² = 85%













Heterogeneity: Tau² = 0.03; Chi² = 30.29, df = 9 (P = 0.0004); I² = 70%

















Heterogeneity: Tau² = 0.05; Chi² = 171.30, df = 13 (P < 0.00001); I² = 92%
Test for overall effect: Z = 6.16 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 295.42, df = 28 (P < 0.00001); I² = 91%
Test for overall effect: Z = 10.53 (P < 0.00001)
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Figure 11. Pooled risk of death among women with a prior diagnosis of early-onset preeclampsia 
versus women with prior normal pregnancy status (a), and among women with a prior diagnosis of 







Figure 12. Pooled risk of death among women with a prior diagnosis of preeclampsia versus 
















Heterogeneity: Tau² = 0.07; Chi² = 37.82, df = 11 (P < 0.0001); I² = 71%
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Heterogeneity: Tau² = 0.15; Chi² = 9.43, df = 4 (P = 0.05); I² = 58%
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Heterogeneity: Tau² = 0.00; Chi² = 1.53, df = 3 (P = 0.67); I² = 0%
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Figure 13. a) Pooled risk of diabetes among women with a prior diagnosis of preeclampsia versus 
women with prior normal pregnancy status - All studies. b) Pooled risk of diabetes among women 
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Heterogeneity: Tau² = 0.05; Chi² = 22.16, df = 8 (P = 0.005); I² = 64%
Test for overall effect: Z = 6.59 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 37.82, df = 11 (P < 0.0001); I² = 71%
Test for overall effect: Z = 7.71 (P < 0.00001)
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Heterogeneity: Tau² = 0.23; Chi² = 184.85, df = 9 (P < 0.00001); I² = 95%
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Figure 14. a) Pooled risk of hypertension among women with a prior diagnosis of preeclampsia 
versus women with prior normal pregnancy status - All studies. b) Pooled risk of hypertension 
among women with a prior diagnosis of preeclampsia versus women with prior normal pregnancy 
















Heterogeneity: Tau² = 0.23; Chi² = 177.87, df = 7 (P < 0.00001); I² = 96%
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Heterogeneity: Tau² = 0.23; Chi² = 1509.30, df = 20 (P < 0.00001); I² = 99%
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Figure 15. a) Pooled risk of anti-hypertensive therapy among women with a prior diagnosis of 
preeclampsia versus women with prior normal pregnancy status - All studies. b) Pooled risk of anti-
hypertensive therapy among women with a prior diagnosis of preeclampsia versus women with 







Figure 16. a) Pooled risk of dyslipidemia among women with a prior diagnosis of preeclampsia 
versus women with prior normal pregnancy status - All studies. b) Pooled risk of dyslipidemia 
among women with a prior diagnosis of preeclampsia versus women with prior normal pregnancy 




















Heterogeneity: Tau² = 0.23; Chi² = 1466.99, df = 14 (P < 0.00001); I² = 99%
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Heterogeneity: Tau² = 0.22; Chi² = 11.75, df = 4 (P = 0.02); I² = 66%
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Heterogeneity: Tau² = 0.27; Chi² = 9.17, df = 1 (P = 0.002); I² = 89%
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Figure 17. a) Pooled risk of kidney disease among women with a prior diagnosis of preeclampsia 
versus women with prior normal pregnancy status - All studies. b) Pooled risk of kidney disease 
among women with a prior diagnosis of preeclampsia versus women with prior normal pregnancy 











Heterogeneity: Tau² = 0.00; Chi² = 1.56, df = 2 (P = 0.46); I² = 0%
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Heterogeneity: Tau² = 0.13; Chi² = 1.56, df = 1 (P = 0.21); I² = 36%
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Heterogeneity: Tau² = 0.41; Chi² = 227.69, df = 13 (P < 0.00001); I² = 94%
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Figure 18. a) Pooled risk of metabolic syndrome among women with a prior diagnosis of pre-
eclampsia versus women with prior normal pregnancy status - All studies. b) Pooled risk of 
metabolic syndrome among women with a prior diagnosis of preeclampsia versus women with prior 








Figure 19. Pooled risk of composite adverse cardiovascular events among women with a prior 
diagnosis of early-onset preeclampsia versus women with a prior diagnosis of late-onset 
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Heterogeneity: Tau² = 0.00; Chi² = 2.54, df = 4 (P = 0.64); I² = 0%
































Odds Ratio Odds Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100







Heterogeneity: Tau² = 0.00; Chi² = 1.65, df = 3 (P = 0.65); I² = 0%
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Figure 20. Pooled risk of cardiovascular and cerebrovascular diseases among women with a prior 
diagnosis of early-onset preeclampsia versus women with a prior diagnosis of late-onset 




Figure 21. Pooled risk of hypertension among women with a prior diagnosis of early-onset 
preeclampsia versus women with a prior diagnosis of late-onset preeclampsia - All studies. 
 
 
Figure 22. Pooled risk of dyslipidemia among women with a prior diagnosis of early-onset 
preeclampsia versus women with a prior diagnosis of late-onset preeclampsia - All studies. 
 
 
Figure 23. Pooled risk of kidney disease among women with a prior diagnosis of early-onset 
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Heterogeneity: Tau² = 0.00; Chi² = 0.06, df = 1 (P = 0.81); I² = 0%
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Figure 24. Pooled risk of metabolic syndrome among women with a prior diagnosis of early-onset 
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